IGHE and allergic respiratory disease: For example, it has been shown that by incorporating additional endpoints into the LLNA (e.g., serum IgE, circulating cytokine levels), these markers can help identify compounds that may pose a particular risk for the development of antibody-mediated respiratory allergy (Dearman et al. 2003).